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ABSTRACT
Although endoscopic surveillance of patients with
Barrett’s oesophagus has been widely implemented,
its effectiveness is debateable. The recently reported low
annual oesophageal adenocarcinoma risk in population
studies, the failure to identify most Barrett’s patients at
risk of disease progression, the poor adherence to
surveillance and biopsy protocols, and the significant risk
of misclassification of dysplasia all tend to undermine
the effectiveness of current management, in particular,
endoscopic surveillance programmes, to prevent or
improve the outcomes of patients with oesophageal
adenocarcinoma. The ongoing increase in incidence
of Barrett’s oesophagus and consequent growth of the
surveillance population, together with the associated
discomfort and costs of endoscopic surveillance, demand
improved techniques for accurately determining individual
risk of oesophageal adenocarcinoma. More accurate
techniques are needed to run efficient surveillance
programmes in the coming decades. In this review,
we will discuss the current knowledge on the
epidemiology of Barrett’s oesophagus, and the
challenging epidemiological dilemmas that need to be
addressed when assessing the current screening and
surveillance strategies.
INTRODUCTION
In 1952, the incidence of oesophageal adenocarcin-
oma (OAC) was low enough that an OAC in
Barrett’s oesophagus (BO) merited a case report.1
OAC has now become the fifth leading cause of
cancer-related death in men worldwide,2 with its
incidence continuing to rise inexorably in the
Western world.3 4
The dismal prognosis of OAC has focused inter-
est on BO, its precursor lesion and a very common
condition in western countries.5 6 BO is defined by
replacement of oesophageal squamous epithelium
by columnar epithelium with intestinal metaplasia
as a consequence of gastro-oesophageal reflux
disease (GORD).7 The cascade of GORD to BO
and ultimately OAC offers attractive targets for
screening and surveillance. These interventions aim
to decrease mortality and improve survival related
to OAC by early detection and treatment of either
dysplastic BO tissue or early cancer. Endoscopic
surveillance of BO has been recommended in
various guidelines by different gastroenterological
societies, and as such, has been widely implemen-
ted.8–13 However, as current evidence for either
improved survival or cost effectiveness is equivocal
at best, the efficacy of BO surveillance remains the
subject of heated debate.14–16 This uncertainty also
limits the basis for population BO screening.
In view of new epidemiological data that have
become available since the development of surveil-
lance guidelines, reconsideration of effective pre-
ventive strategies for BO patients seems justified.
This review will provide an overview of our current
knowledge on the epidemiology of BO and the
challenging epidemiological dilemmas that need to
be addressed when reassessing screening and sur-
veillance strategies.
EPIDEMIOLOGY OF BO
The epidemiology of BO is especially complicated
because the majority of affected individuals are
asymptomatic and remain undiagnosed.17 Those
patients who come to medical attention are likely
to represent a subpopulation that may very well
differ from those who remain undiagnosed.
Published epidemiological data can, therefore, only
be an approximation of the true prevalence of BO.
Prevalence of BO in the general population
Most prevalence data have been derived from BO
diagnoses made during oesophagogastroduodeno-
scopy (OGD) performed for dyspeptic symptoms,
however, BO prevalence has been studied in unse-
lected populations. An overall BO prevalence of
6.8% was found in a cohort of 961 patients under-
going colonoscopy that were offered an additional
OGD. Short-segment BO (SSBO) was relatively
common in persons aged 40 years or older (5.5%),
irrespective of heartburn history.18 A similar
colonoscopy-based study, limited to 300 subjects
over age 65 years, found long segment BO (LSBO)
in 4% and SSBO in 15%. There was no significant
relation with reflux symptoms.19
So far, three population-based studies have
addressed the prevalence of BO in the general
population. Ronkainen et al20 performed upper
endoscopy in a random sample of 1000 Swedish
adults. BO was found in 1.6%, long segment in
0.5%, and short segment in 1.1%. Other
population-based studies in Italy and China
reported a BO prevalence of 1.3% and 1.9%, with
LSBO in 0.2% and 0.5% of patients, respect-
ively.21 22 These estimates indicate that approxi-
mately 0.5–1.5% of western populations would
need to be offered regular endoscopic surveillance,
according to current guidelines, if BO surveillance
programmes are to be implemented.
Age, sex and ethnic distribution of BO
A British endoscopy study reported a 7% annual
increase in prevalence of BO for both sexes. For
men this increase started at age 20 years, however,
in women it was delayed until age 40 years,
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resulting in a 20-year age shift and an overall 2:1 male predom-
inance among BO cases.23 A large Dutch general practice regis-
try confirmed the parallel age-specific increases in BO, with a
similar 20-year age shift between men and women.24 The
Northern Ireland BO registry which included over 9000 BO
patients, also noted significantly fewer women than men diag-
nosed with BO in the age group of 16–40 years.25 This delayed
development of BO is consistent with the 17-year delay in
female OAC incidence, leading to an overall 3.5:1 male predom-
inance, presumably as a result of women acquiring BO at an age
when they die from other causes before developing OAC.26 27
This observation may relate to an endogenous protective effect
related to sex-specific hormone production observed in preme-
nopausal women, most likely oestrogen, which is known for its
anti-inflammatory effects in certain tissues.11 12 The relationship
between the prevalence of reflux oesophagitis and obesity in
women suggests that this hormonal protection for women may
disappear with their tendency to gain weight during perimeno-
pause.28 The interaction between oestrogen and obesity in this
respect needs further study.
Apart from these gender-related differences in BO epidemi-
ology, there are also marked ethnic differences. A report from
the USA based on Surveillance, Epidemiology and End Results
(SEER) data noted far higher OAC rates in Caucasian white
males than in black American males, with female rates far lower
for both ethnic groups.3 29 In the UK, a higher BO prevalence
in white Caucasians compared with Asians was reported.30 Data
on the prevalence in Hispanics are contradictory, with some
studies showing a similar prevalence to that in Caucasians,31
and other studies showing a lower prevalence.32 33
Increasing incidence of BO in the general population
The dramatic increase in the incidence of OAC over the past
decades is thought to have been preceded by a similar steep
increase in incidence of BO. Methodological problems have,
however, confused the measurement of actual BO incidences.34–36
Some of the reported increases in newly made diagnoses are a
result of more widespread use of endoscopy, increased awareness
of BO among endoscopists, and higher oesophageal biopsy rates.
However, a 93% increase in BO incidence between 1993 and
2005 was published from the Northern Ireland BO registry, where
the potential confounding by number of endoscopies was avoided
by counting the number of BO cases per 100 endoscopies.37
A similar Dutch study also reported an increase in BO incidence
irrespective of numbers of performed OGDs. Importantly, the
increased incidence was most pronounced among men under
60 years of age, suggesting a birth cohort effect, which might be
related to increasing affluence after World War II.38 Similar cohort
phenomena in OAC incidence have been demonstrated in the USA
and Australia.39 40 Additionally, recent Dutch data reported a con-
tinuing rise in OAC and a decline in gastric cardia adenocarcinoma
incidence.41
Explanations for the increasing BO incidence
One popular explanation for the increasing incidence of BO in
western countries is the decreasing prevalence of gastric colon-
isation with Helicobacter pylori.42 A population-based study
provided evidence that absence of H pylori colonisation was
associated with BO.43 The suggested mechanisms for the inverse
association include decreased acid production through gastric
atrophy by H pylori infection44 45 and enhancement of gastric
emptying, especially in younger persons.46 A parallel between
the aforementioned birth cohort effect in BO incidence, and
that of the prevalence of H pylori was also reported.47 48 The
considerably lower OAC rates in countries with a high preva-
lence of H pylori also provide support for this hypothesis.49–51
However, H pylori infestation can also augment acid produc-
tion. The OAC incidence of Swedish inpatients treated for duo-
denal ulcer during the 1960s considerably exceeded that of
their contemporary gastric ulcer patients and the general
Swedish population.52 Furthermore, the H pylori hypothesis
fails to explain the male predominance and ethnic differences in
BO and OAC incidence.
Therefore, an alternative hypothesis to explain the increasing
prevalence of BO and OAC that is based on the prevalence of
obesity has been proposed and is gaining popularity. This
hypothesis proposes that the mounting prevalence of obesity, in
particular visceral obesity, is responsible for the rising incidences
of BO and OAC. Ryan et al53 found abundant evidence for
obesity as the driving force behind the rising OAC rates. Obesity
has been associated with a significant 1.5-fold to 2-fold increase
in the risk of GORD symptoms and erosive oesophagitis, and a
2-fold to 2.5-fold increase in the risk of OAC.54 Possible
mechanisms mediating this association include increased intra-
gastric pressure and gastro-oesophageal pressure gradient,55
more frequent transient relaxations of the lower oesophageal
sphincter,56 and increased oesophageal acid exposure.57
Two large case-control studies from the USA have reported
that in particular, abdominal circumference (ie, waist-hip ratio),
but not body mass index (BMI), was an independent risk factor
of BO.58 59 A study among veterans based on CT scans showed
that visceral adipose tissue but not BMI was independently asso-
ciated with BO.60 The suggested mechanism could relate to the
induction of a systemic pro-tumorigenic inflammatory state as a
result of adipocytokines and pro-coagulant factors released by
adipocytes in abdominal visceral adipose tissue. A high preva-
lence of metabolic syndrome in BO, especially in LSBO, with
increased cytokine and fasting insulin levels, as compared to
SSBO patients has been found.61 Additionally, visceral adipose
tissue has also been strongly associated with increased serum
levels of interleukin 6 (IL-6), tumour necrosis factor α (TNF-α),
and C-reactive protein,62 as well as with leptin, which may
stimulate cell proliferation and inhibit apoptosis in
Barrett’s-derived OAC cells.63
Visceral obesity may well help to further explain several epi-
demiological features of BO such as the sex and ethnic differ-
ences. A much stronger association between increasing BMI and
GORD symptoms has been observed among whites than among
black subjects and Asians,64 while white males have more vis-
ceral adipose tissue than black males.65 Another US study
revealed that, at the same age and level of adiposity, black men
and women had less visceral adipose tissue than white men and
women, these differences were greater in men than in women.66
Visceral adipose tissue was also higher in white than in black
postmenopausal women, although the latter had higher levels of
subcutaneous fat.67 After menopause, visceral adipose tissue has
been shown to increase in European–American, but not in
African–American women.68 However, larger amounts of vis-
ceral adipose tissue were observed in Asian Americans than in
white subjects.69 Genome-wide studies have identified a number
of genetic loci involved in abdominal fat distribution, BMI and
obesity.70 71 Further studies between the association of BO and
these genetic loci to confirm these observations are now
indicated.
Based on these correlations, it is plausible to assume that the
steadily increasing prevalence of obesity,72 73 in particular, vis-
ceral obesity in many populations, will drive an increase in inci-
dence of BO and OAC.
192 de Jonge PJF, et al. Gut 2014;63:191–202. doi:10.1136/gutjnl-2013-305490
Recent advances in clinical practice
group.bmj.com on March 4, 2016 - Published by http://gut.bmj.com/Downloaded from 
CANCER RISK IN PATIENTS WITH BO
Accurate estimates of the annual incidence of OAC and high-
grade dysplasia (HGD) among patients with BO have been diffi-
cult to obtain, since studies have shown considerable variation
in incidence rates. Published data predominantly have come
from small cohort studies with relatively short follow-up, and
mostly from referral centres, which likely have ascertainment
biases that will show a higher cancer incidence than may be
observed in larger population-based studies. Consequently, in
light of these issues, it is not surprising that evidence of publica-
tion bias in surveillance studies favouring publication of small
studies with high cancer incidence rates has been reported.74
Meta-analyses on cancer risk
Currently, seven systematic reviews have been published on the
cancer risk in patients with BO.74–80 The pooled estimates for
the annual OAC incidence among BO patients in these reviews
varied between 0.3% and 0.6%, and between 0.9% and 1.0%
for the combined incidence of HGD and OAC (table 1).
It should be noted that two reports failed to exclude early
incident cancers (detection within 1 year after baseline diagnosis
of BO),74 75 and three included cancers occurring in patients
with HGD at baseline,74–76 thereby inflating risk of OAC.
In order to obtain more accurate estimates of the risk of OAC
in BO patients, analysis of the data derived from high-quality
studies (large study size, robust definition of BO) has been per-
formed and has tended to show a lower cancer risk. This ana-
lysis revealed that the annual OAC incidence rates in BO
cohorts with less than 2000 patient years widely ranged
between 0 and 3.55%, and fell to 0.07–0.82% in cohorts with
more than 2000 patient years of follow-up.78 The reliability of
OAC incidence rates thus appears to depend on the size of the
cohort and duration of follow-up. Besides the obvious higher
chance of random deviation from the norm in small studies,
there are a number of potential confounders that can strongly
influence outcomes such as variations between cohorts in the
male to female ratios, and age at BO ascertainment. A less
obvious confounder is the proportion of the cohort lost to
follow-up, with the resultant loss of follow-up years and OAC
ascertainment, resulting in unreliable high OAC incidence
rates.81
Population-based cohort studies
Recently, three population-based BO follow-up studies were pub-
lished in which national cancer registries provided complete
ascertainment of OAC incidence.6 82 83 Inclusion in the BO
cohorts was based on national histopathology registries, while
inclusion in the third study was based on an endoscopy registry83
(table 2). The design of these studies strongly reduced selection
bias, which has been a particular limitation of previous cohort
studies. The first and largest study consisted of 42 207 patients
entered in a Dutch nationwide histopathology registry between
1991 and 2006 with a first diagnosis of BO with intestinal meta-
plasia and including either no concurrent dysplasia or, at most,
low-grade dysplasia (LGD).6 Subsequent histological events were
monitored until November 2007, or a diagnosis of OAC or HGD
was made. The number of patient years for the remainder of the
cohort was estimated from survival data from the general Dutch
population. For BO patients undergoing endoscopic follow-up
after baseline diagnosis, the annual OAC risk was 0.4%;
however, when cancer risk was analysed for all BO patients,
regardless of whether any follow-up was performed, the annual
OAC risk dropped to 0.14%, with 0.19% in men and 0.08% in
women.
The second study comprised 11 028 BO patients with intes-
tinal metaplasia, with or without LGD, enrolled in the Danish
Pathology Registry from 1992 through 2009.82 The civil regis-
tration number assigned to all Danes enabled data linkage of all
medical registries and dates of emigration or death. After again
eliminating all OAC cases occurring in the first year after index
BO diagnosis, the authors found an annual OAC risk of 0.12%
for the entire cohort, 0.15% for men and 0.05% for women.
The last study was the third update of the Northern Ireland
BO registry cohort, comprising every adult diagnosed with BO
in Northern Ireland between 1993 and 2005.83 The cohort
includes 8522 BO patients, with or without intestinal metapla-
sia, followed until the end of 2008. The ascertainment of OAC
was achieved by matching BO registry data with that of the
Northern Ireland Cancer Registry. Besides including BO without
intestinal metaplasia at index biopsy, the cohort differed from
the two previous studies in that for some patients endoscopic
Table 2 Overview of results from nation-wide population-based
incidence studies of oesophageal adenocarcinoma (OAC) in
unselected patients with Barrett’s oesophagus (BO)
Variable
BO
patients
(n)
Incident
OAC (n)
Person-years
of follow-up
OAC
incidence
(% per
year) 95% CI
de Jonge et al6
BO all 42.207 337 234.821 0.14 0.12 to 0.16
Male 25.890 259 136.316 0.19 0.17 to 0.21
Female 16.317 78 97.505 0.08 0.07 to 0.10
Bhat et al83
BO all 8.522 79 59.784 0.13 0.10 to 0.16
Male 4.936 19 34.493 0.17 0.13 to 0.22
Female 3.586 60 25.272 0.08 0.05 to 0.12
Hvid-Jensen
et al82
11.028 66 56.782 0.12 0.09 to 0.15
BO all
Male 7.366 56 37.771 0.15 0.11 to 0.19
Female 3.662 10 19.011 0.05 0.03 to 0.10
BO, Barrett’s oesophagus.
Table 1 Overview of results from meta-analyses on oesophageal
adenocarcinoma (OAC) risk in patients with Barrett’s oesophagus
(BO)
References Studies (n)
OAC incidence
rate* (95% CI)
HGD/OAC incidence
rate (95% CI)
Shaheen et al74 25 5.0 (n/a) –
Chang et al75 14 6.3 (3.6 to 10.1) –
Thomas et al76 41 7 (6 to 9) 9 (5 to 16)
Yousef et al77 47 4.1 (3.1 to 5.5) 9.3 (6.3 to 14)
Wani et al79
NDBO 45 6.0 (5.1 to 6.9) –
LGD 16 17 (13 to 21) –
Sikkema et al78 50 6.3 (4.7 to 8.4) 10.2 (7.5 to 14)
Desai et al80
NDBO 57 3.3 (2.8 to 3.8) –
*Incidence rate per 1000 person-years.
HGD, high-grade dysplasia; LGD, low-grade dysplasia; n/a, not available; NDBO,
non-dysplastic Barrett’s oesophagus; OAC, oesophageal adenocarcinoma.
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data were available. An annual cancer risk of 0.13% for the
entire cohort was found; 0.17% for men and 0.08% for
women.
Some limitations of these studies warrant consideration. First,
all three studies included the incidence of HGD as an outcome.
As these were observational cohorts, and HGD is often asymp-
tomatic, its ascertainment was far inferior to that of OAC and,
consequently, its incidence was considerably underestimated.
Second, sampling error and misclassification of dysplasia status
may have affected the published results. Third, some patients
with intestinal metaplasia of the cardia could have been misclas-
sified as having BO, as endoscopic data were not provided.
Nevertheless, the study size, population-basis, low ‘loss to
follow-up’ rates, and high OAC ascertainment, though linkage
of histology and cancer registries are major advantages of these
studies. Additionally, the finding of remarkably similar absolute
annual risks of 0.12–0.14% provides support that these studies
are reporting accurate incidence data. Consequently, these
studies have changed the views on BO-associated cancer risk
and have set new standards for assessing OAC risk in BO.
Risk of mortality in patients with BO
Whether patients with BO have an increased mortality risk from
causes either related or unrelated to OAC compared with the
general population remains controversial.34 84–90 In studies
reporting an excess mortality, this was primarily due to extra-
oesophageal diseases such as pneumonia and, in particular, car-
diovascular disease. It may well be that patients with pre-existing
illness are more likely to have endoscopy and to have BO found
than other members of the population.34 Additionally, increased
mortality due to cardiovascular disease in BO may result from a
shared association with obesity.
SCREENING FOR BO
The high prevalence of BO and its expected mounting incidence
in the general population which heralds a further increase in
OAC incidence, can be seen as arguments for targeted popula-
tion screening for BO. Based on the epidemiological data
described above, this approach would seem to be a plausible
and necessary step to ultimately decrease OAC-related mortality.
In order to achieve this goal, subjects at risk of BO would need
to be identified, and either treated or monitored under surveil-
lance, or both. However, for these approaches to have optimal
efficacy, methods for the accurate assessment of an individual’s
cancer risk are needed.
Predictors of BO
BO is associated with increasing age, male gender, Caucasian
race and visceral obesity,78 91 92 but symptomatic GORD
remains its best known risk factor. While the severity of reflux
symptoms fails to distinguish between reflux oesophagitis and
BO,93 a long duration of reflux symptoms seems a better indica-
tor of the presence of BO.94 95 In a community-based study, as
compared with patients with GORD symptoms for less than
1 year, the relative risk of BO was respectively 3.0 and 6.4 for
patients with reflux symptoms for 1–5 years and >10 years.96
Cigarette smoking is also a modest risk factor for BO.97 A
recent analysis from five case-control studies reported adjusted
ORs in the range of 1.5–2; the association strengthened with
increased exposure to smoking until approximately 20 pack-
years.98 Currently there is no evidence that alcohol intake
increases the risk of BO.99 100 Two other studies have even sug-
gested an inverse association between BO and wine consump-
tion.101 102 Families with BO and OAC in multiple relatives
over successive generations have been reported, suggesting a
heritable component to BO and OAC.103–105 One study showed
that familial BO was present in 30 (7.3%) of 411 probands with
either LSBO, OAC or adenocarcinoma of the gastro-oesophageal
junction, comprising 17 of 276 (6.2%) with BO, 11 of 116
(9.5%) with OAC, and 2 of 21 (9.5%) with adenocarcinoma of
the gastro-oesophageal junction.106 Another study reported a
24% BO prevalence among first-degree members of BO index
cases.107 A segregation analysis involving data on 881 singly
ascertained pedigrees provided epidemiologic evidence in
support of one or more rare autosomally inherited dominant
susceptibility allele(s) in BO families, and, hence, motivated
linkage analyses.108 Germline mutations in the MSR1, ASCC1,
and CTHRC1 genes have been associated with the presence of
BO and OAC,109 and a recent genome-wide association study
(GWAS) study with 5986 BO cases and 12 825 controls in the
replication stage found that genetic variants at two loci were
associated with BO risk; one located at chromosome 6p21
within the major histocompatibility complex, and one on
chromosome 16q24 for which the closest protein-coding gene
was FOXF1, which is a transcription factor involved in oesopha-
geal development and structure.110
Current guidelines for screening for BO
Currently, the American Gastroenterological Association (AGA)
position statement on the management of BO recommends
enrolling patients with multiple risk factors associated with
OAC in screening programmes, although this was classified as a
weak recommendation with moderate-quality evidence.9 The
committee recommended against screening all patients with
GORD. This statement corresponds to the American Society for
Gastrointestinal Endoscopy (ASGE) guidelines,11 and to the
updated guideline from the British Society of Gastroenterology
(BSG) yet to be published.13 The French Society of Digestive
Endoscopy (SFED) recommends against screening and does not
make exceptions for any subgroups of patients.10 In the absence
of randomised controlled trials of endoscopic screening, some
cost effectiveness modelling studies have indicated that screening
programmes may be cost effective,58 59 whereas other modelling
studies have not.60
Dilemmas in screening for BO
One major dilemma that diminishes the usefulness of screening is
that a significant proportion of BO patients lack reflux symptoms
(box 1). In population-based studies of the prevalence of BO, over
45% of identified BO patients did not report symptoms of
GORD.20 21 Additionally, even in patients with OAC, approxi-
mately 40% have no GORD history prior to diagnosis.111
Therefore, symptomatic GORD as a selection criterion for endo-
scopic screening is likely to exclude half the BO population. In
fact, even if one accepts GORD as an entry criterion, a second
dilemma is that the at-risk population is very large, as GORD
symptoms are ubiquitous in the general population, with a
Box 1 Dilemmas with screening for Barrett’s
oesophagus (BO).
▸ Significant proportion of BO patients and those with
oesophageal adenocarcinoma lack reflux symptoms.
▸ At-risk population for BO is too broadly characterised.
▸ Endoscopy is invasive and expensive as a screening tool.
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prevalence of 15–20% in the Western world, and an incidence of
approximately 5/1000 person-years.112 Implementation of a
screening programme for BO based on GORD symptoms would,
consequently, create a huge burden on the healthcare system,
which is difficult to justify at this time given the paucity of data
demonstrating a benefit of BO screening programmes on health
outcomes. Another question that would need to be addressed in a
BO screening programme is that of the age at which screening
should be initiated. The yield of BO will be higher in older popula-
tions, however, in view of the long incubation period between the
onset of BO and OAC, the majority of the elderly BO subjects are
unlikely to develop OAC. Therefore, screening at age 40 would
probably identify a higher proportion of BO patients who will
ultimately develop OAC. However, these subjects would then be
committed to decades of endoscopic surveillance with limited
benefit per screening session given the low annual cancer risk.
There are also substantial problems with the execution of
various facets of endoscopic screening and surveillance pro-
grammes, such as false BO diagnosis through biopsies of the
gastric cardia, resulting in unnecessary patient anxiety, unneces-
sary follow-up examinations, and, in the USA, increased
expense and difficulty in obtaining life and other insurance.113
Additionally, OGD is relatively expensive,114 and carries a,
albeit small, risk of complications, which becomes important
when applied to large populations in a screening setting.115 116
Furthermore, the procedure is obviously burdensome to many
patients,117 especially since patients diagnosed with BO may
overestimate their cancer risk, contributing to a decreased
quality of life.118 These limitations all favour restricting the use
of endoscopic procedures for BO screening in large, population-
based screening programmes (box 1).
Potential new minimally invasive screening modalities
Less invasive technology may solve the latter problem. In a
study offering unsedated transnasal endoscopy and video
capsule endoscopy as alternatives to sedated endoscopy, partici-
pation rates were 50%, 59% and 38%, respectively, which sug-
gests that less invasive methods are preferable to patients.119
Ultrathin video endoscopes can easily be passed transorally or
transnasally, providing an efficient, cost-effective alternative to
standard sedated endoscopy.120 However, so far it has not been
shown to result in a large increase in the number of primary
care referrals for BO screening with unsedated ultrathin
OGD.121 This could be the result of many factors, for example,
the unwillingness of some patients to undergo unsedated proce-
dures, and the lack of service provision for nasal endoscopy at
many hospitals.
Oesophageal capsule endoscopy (OCE) offers a method of
visualising the oesophagus without the discomfort and risks of
OGD. Initial pilot studies have demonstrated a high diagnostic
yield of BO, a high patient preference, and no safety pro-
blems.122 123 However, a meta-analysis of nine studies on the
diagnostic accuracy of OCE for BO have reported a relatively
low sensitivity (77%) and specificity (86%) for detecting BO.124
These suboptimal test performances, together with the current
high cost of capsules and the inability to biopsy any detected
BO are obvious disadvantages to OCE and preclude OCE as a
screening test for BO in GORD patients.
Currently, the most promising alternative to endoscopic
screening is the Cytosponge test, which is based on an ingestible
oesophageal sampling device that allows cytology samples to be
retrieved from the oesophagus. These samples can then be used
in immunohistochemical assays of trefoil factor 3. It has an
acceptable sensitivity and specificity for BO (73% and 94%,
respectively), is easily applicable in primary care, and well toler-
ated by most patients.125 126 Furthermore, the binary scoring
for trefoil factor 3 makes the test amenable to automation.
A cost-effective model showed that screening based on the
Cytosponge assay in 50-year-old men with symptoms of GORD
followed by treatment of patients with dysplasia or intramucosal
cancer is cost effective and would reduce mortality from OAC
compared with no screening.127 Further validation of the
Cytosponge test in different communities is required to assess
its potential role in future BO screening. The most ideal screen-
ing test, however, would be based on the use of serum biomar-
kers, which are under development, and which may be available
in the future.
SURVEILLANCE OF PATIENTS WITH BO
Once BO is diagnosed, patients are offered endoscopic surveil-
lance in order to detect high-risk BO (eg, BO with HGD) or
early stage cancers suitable for curative treatment. Several
factors need to be considered in individual patients before start-
ing endoscopic surveillance, such as age, comorbidity, the
patient’s understanding of limitations of endoscopic surveil-
lance, and the willingness of the patient to adhere to be compli-
ant with the endoscopy-based surveillance programme.
Current guidelines for endoscopic surveillance
The majority of societal guidelines base the interval of surveillance
endoscopy solely on the histological evaluation of biopsy samples,
but usually not take other factors into account, such as, for
example, age, gender and BO segment length (table 3). For BO
patients without dysplasia, current guidelines by the American
College of Gastroenterology (ACG) recommend surveillance
endoscopy at 3-year intervals. For patients with LGD, annual sur-
veillance endoscopy is recommended, and for those with HGD
who receive no invasive therapy, intensive endoscopic surveillance
exams every 3 months is recommended.8 The ASGE and the AGA
medical position statements on the management of BO recom-
mend intervals between 3 and 5 years for non-dysplastic BO
(NDBO).9 11 The SFED does correlate the surveillance interval for
patients with no dysplasia (ND) to the length of the BO segment;
in those with SSBO surveillance endoscopy should be performed
every 5 years, in those with a segment length of 3–6 cm, every
3 years, and in those with segments longer than 6 cm, every
2 years.10 Contrasting with the recommendations in the BSG
guideline from 2006, the recently revised guideline also takes the
length of the Barrett’s segment into account, with recommended
surveillance intervals every 2–3 years for non-dysplastic LSBO,
and 3–5 years for those with SSBO.13
Dilemmas in endoscopic surveillance of Barrett’s
oesophagus
Although surveillance endoscopy is intuitively rational and
endorsed by international gastroenterological societies, the data
supporting many aspects of the recommended strategies are
based on equivocal data. Consequently, most recommendations
are classified as weak. More importantly, there are no prospect-
ive randomised controlled trials unequivocally demonstrating a
beneficial effect of endoscopic surveillance on OAC mortality.
Retrospective studies have shown that patients with OAC were
more likely to have their cancer detected at an earlier stage
when they had previously been in a surveillance programme
compared to those patients not under surveillance.128
Furthermore, early recognition of HGD or cancer has been
associated with an improved survival from OAC.129 However,
results of non-randomised comparisons between surveillance
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and non-surveillance-detected cancers are hindered by a variety
of factors including lead time and length bias, which falsely
associate surveillance programmes with improved outcomes.130
One further problem with surveillance is that, although the
vast majority of OAC cases arise in the setting of BO, only a
small proportion of BO patients will eventually develop
OAC,6 131 and even less will eventually die from OAC. In a
Dutch cohort study, only 5.6% of total mortality among BO
patients was related to OAC.84 Another observational study fol-
lowing a cohort of 409 BO patients for 10 years showed that
only four (1.0%) of them died as a result of OAC.81 Moreover,
an estimated 95% of patients with a new diagnosis of OAC do
not have a previous diagnosis of BO,17 suggesting that for the
general population, BO surveillance programmes will only have
a modest effect on OAC mortality.
Several authors have used mathematical models to explore the
cost effectiveness of BO surveillance.132–134 US researchers con-
cluded that, for a cancer risk of 0.5% per annum, surveillance
every 4 years was indicated, but if the annual risk was 0.4%,
surveillance every 5 years was the only viable cost-effective strat-
egy.134 Others reported that screening 50-year-old men with
GORD to detect adenocarcinoma was probably cost effective
when subsequent surveillance was limited to BO patients with
dysplasia ($10440 per quality adjusted life year (QALY)).
Screening was, however, far too expensive when surveillance
was also performed in NDBO patients, even at 5-yearly intervals
(additional $596000 per QALY).133 A British cost-efficacy study
reported that at an annual cancer risk of 0.5%, BO surveillance
conferred less benefit and more costs than no surveillance at all,
irrespective of the surveillance interval used.132 The outcomes
of all these modelling studies were strongly influenced by prede-
fined parameters, the most critical of which was the annual inci-
dence of OAC among BO cases, with most assuming 0.4–0.5%,
which is the incidence still employed in current surveillance
guidelines.8 Consequently, the observed 0.12–0.14% incidence
from the population studies will only further provide support
against the cost effectiveness of surveillance.
The execution of surveillance is also beset by technical pro-
blems. As dysplasia in Barrett’s mucosa is often patchy, its diag-
nosis is subject to sampling error when biopsy-based sampling
methods are used for its detection.135 In a retrospective study
on 68 patients who underwent an oesophagectomy for HGD,
12 were diagnosed with adenocarcinoma in the resection speci-
men, of which eight were invasive cancers.136 Additionally, in a
Danish study of newly diagnosed BO patients, more than
two-thirds of all OACs were diagnosed during the first year of
follow-up, indicating sampling error at the index biopsy.82
Extensive biopsy sampling, known as the Seattle biopsy proto-
col, has been recommended for decreasing sampling error, but
is unable to eliminate the problem entirely, because even if it is
properly performed, only 4–6% of the BO area can be
sampled.137 Although the protocol has been associated with
increased detection of dysplasia and invasive cancer,138 in daily
practice, adherence to such a rigorous endoscopic surveillance
protocol seems to be poor, and compliance is inversely asso-
ciated with the length of the BO segment. In a Dutch retrospect-
ive study of endoscopy and pathology reports, adherence to the
Seattle protocol was as low as 30%, in particular, among BO
patients with segments of 10–15 cm in length.139 A similar US
study reported an overall adherence of only 51%, with evidence
that failure to protocol adherence was associated with decreased
rates of dysplasia detection.140 These findings suggest that for
those BO patients at highest risk of development of OAC,
adherence appears to be the poorest. Advanced endoscopic tech-
niques, such as chromoendoscopy, narrow-band imaging (NBI)
and autofluorescence endoscopy, which are intended to enhance
the detection of dysplastic areas for biopsy sampling, are prom-
ising,141 although they have not consistently been shown to
increase neoplasia detection as compared with high-resolution
white-light endoscopy (figure 1). A recent randomised con-
trolled trial showed that use of NBI-targeted biopsies and the
current standard of random four-quadrant biopsies diagnosed
similar proportions of patients with BO, although NBI could
achieve this with significantly fewer biopsies, suggesting
improved efficiency and consequent cost reduction.142
However, as the study was limited to three tertiary BO referral
centres, these results cannot be directly extended to non-tertiary
centres. Given the poor adherence to the surveillance biopsy
protocol, especially in those patients who are presumed to
benefit the most of endoscopic surveillance, it should be consid-
ered to refer patients with longer segments of BO to tertiary
centres for surveillance by an endoscopist experienced in
Table 3 Guidelines for endoscopic surveillance of Barrett’s oesophagus (BO) by gastroenterological societies
Grade of
dysplasia ACG ASGE AGA BSG SFED
NDBO Two OGDs within first year, then
every 3 years if no dysplasia
Consider no surveillance. If
surveillance is elected, OGD
every 3–5 years
OGD every 3–5 years SSBO (<3 cm): OGD every
3–5 years
LSBO (> 3 cm): OGD every
2–3 years
SSBO (< 3 cm): OGD every
5 years
LSBO (3–6 cm): OGD every
3 years
LSBO (> 6 cm): OGD every
2 years
LGD* Repeat OGD within 6 months; if
no HGD, then every 1 year
Repeat OGD within 6 months;
if no HGD, then every 1 year
OGD every 6–12 months Repeat OGD within
3 months; if no HGD, then
every 6 months
Repeat OGD. If LGD
confirmed, OGD at
6 months, 1 year, then
yearly
HGD* Repeat OGD within 3 months,
then every 3 months or consider
endoscopic therapy
Consider repeat OGD within
3 months or endoscopic
therapy
OGD every 3 months in
the absence of
endoscopic therapy
Consider endoscopic
therapy
Repeat OGD. If HGD
confirmed, endoscopic or
surgical treatment
*Confirmation of presence and grade of dysplasia by an expert gastrointestinal pathologist.
AGA, American Gastroenterological Association; ASGE, American Society for Gastrointestinal Endoscopy; BSG, British Society of Gastroenterology; HGD, high-grade dysplasia; LGD,
low-grade dysplasia; LSBO, long segment BO; NDBO, non-dysplastic Barrett’s oesophagus; OGD, oesophagogastroduodenoscopy; SFED, French Society of Digestive Endoscopy; SSBO,
short segment BO.
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specialised imaging modalities. A limitation, however, could be
that given the ongoing increase in incidence of BO in the
general population, this policy may create a huge burden on the
healthcare system of tertiary hospitals. Therefore a cut-off
length should be defined for identification of candidates for cen-
tralised surveillance. Additionally, it remains to be shown that
such referral has no negative impact on patient adherence.
The substantial disagreement among pathologists in assessing
the presence and grade of dysplasia has also raised concerns
about the use of surveillance programmes that depend on accur-
ate determinations of dysplasia in BO. The interobserver agree-
ment in differentiating HGD from intramucosal cancer is only
fair,143 while the interobserver agreement for the distinction
between ND and LGD is poor.144 145 A retrospective study of
the natural history of LGD in a community-based cohort of BO
patients demonstrated that following review by two expert
pathologists, 85% of patients with an initial diagnosis of LGD
could be downstaged to ND or indefinite for dysplasia, while
those with a consensus diagnosis of LGD had significantly
higher rates of malignant progression than patients downstaged
to ND.146 These findings indicate that a new diagnosis of LGD
in particular should always undergo expert pathology review.
Furthermore, the diagnosis of dysplasia varies between consecu-
tive surveillance biopsies, which may be a result of sampling
error, but may also indicate the inconsistent nature of this risk
marker. It remains unclear whether dysplasia can regress over
time. Misclassification of the presence and grade of dysplasia
may lead to unnecessary follow-up endoscopies in case of over-
diagnosis, or to possibly insufficient follow-up exams with
inappropriate surveillance intervals in the case of underdiagnosis
(box 2).
RISK STRATIFICATION IN PATIENTS WITH BO
The prolonged interval between BO onset and OAC incidence
implies that the rational management of individual patients will
require the ability to establish in any given BO patient an accur-
ate assessment of risk for developing OAC and the approximate
time to progression. To attain this goal, a prediction model,
preferably based on demographic, environmental, endoscopic,
histological and molecular markers is needed. A systematic
review by Prasad et al147 described the current state of knowl-
edge on predictors of progression in BO in detail. In the follow-
ing paragraph, the current state of predictive factors for OAC is
summarised.
Demographic and environmental risk factors
Male gender remains the most robust demographic factor pre-
dictive of OAC development. Population-based studies, as well
as systematic reviews, have shown a much higher OAC incidence
in men with BO than in women with BO.6 77 82 This finding is
consistent with the strong male predominance in patients with
OAC.29 148 The role of age on the progression in BO is,
however, less clear. Several studies have shown that increasing
age is an independent predictor of OAC development,149 with
the highest incidence of OAC among BO patients older than
70 years of age,82 although other large cohorts could not
confirm this.150 151 A retrospective study from the Cleveland
Clinic BO registry did not show different rates of progression
between BO patients younger and those older than 50 years.152
However, in a prospective observational cohort study from our
centre, patients with a diagnosis of BO as long as 10 or more
years prior to inclusion had a threefold increased risk to
develop HGD or OAC, as compared with patients with a
shorter known duration of BO diagnosis.153 Assuming the exist-
ence of an incubation period of three or four decades between
BO onset and OAC development,154 and that the prevalence
of BO increases with age, the smaller number of patients acquir-
ing BO around their fourth decade are far more likely to survive
long enough to develop OAC as compared with the great major-
ity acquiring BO in their fifth and sixth decades. Consequently,
Box 2 Dilemmas with surveillance of Barrett’s
oesophagus (BO).
▸ Overall risk of oesophageal adenocarcinoma in BO is low.
▸ Only few patients will eventually die from oesophageal
cancer.
▸ Most cancers are detected outside surveillance programmes.
▸ Biopsy sampling error due to patchy distribution of
dysplasia.
▸ Suboptimal adherence to rigorous biopsy protocol in daily
practice.
▸ Interobserver variability in diagnosing the presence and
degree of dysplasia.
▸ Natural history of dysplasia is unclear.
▸ Surveillance is burdensome for patients.
▸ Current practice is not cost effective.
Figure 1 Barrett’s oesophagus containing early neoplasia; (A) lesion
with white-light endoscopy, and (B) lesion with narrow-band imaging.
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the generally unknown age of BO onset would be far more rele-
vant to prognosis than age itself, if this could be determined.
Malignant progression in BO has also been associated with an
increased BMI at young age,155 and an increased waist to hip
ratio, the latter being associated with an increased proliferation
rate in BO as indicated by an increased percentage of S-phase
cells.156 Additionally, increased waist to hip ratio, a surrogate
marker of visceral adipose tissue distribution, but not BMI, was
shown to be related to the risk of aneuploidy, 17p loss of het-
erozygosity (LOH) and 9p LOH,157 confirming visceral adipose
tissue as a potential predictor of neoplastic progression.
Smoking has, in some studies, been suggested as an additional
risk factor for progression to OAC,155 158 159 while other inves-
tigators did not confirm this.151 153 160
Endoscopic risk factors
Multiple studies have found that length of the BO segment is a
risk factor for development of OAC.158 160–167 A Dutch pro-
spective cohort study of 713 BO patients found that each centi-
metre increase in BO length was associated with an 11%
increase in the risk of developing HGD or OAC.151 Wani
et al168 reported a significant higher risk of OAC in BO seg-
ments longer than 6 cm (0.09%/year) as compared to those
shorter than 6 cm (0.65%/year; p=0.001). In a retrospective
cohort study of 155 patients with SSBO and 93 with LSBO, a
BO segment length >3 cm was found to be associated with dys-
plasia (OR 1.2; 95% CI 1.07 to 1.34).169 The presence of base-
line dysplasia can be an important confounder of these
associations between BO length and OAC incidence. In a large
prospective cohort study, after adjustment for histology at study
entry, segment length was not a significant predictor of progres-
sion.166 However, a recent meta-analysis on cancer risk in
NDBO patients, reported an overall OAC risk of 0.33% (95%
CI 0.28% to 0.38%), but only 0.19% for SSBO patients
without dysplasia.80 It further remains to be clarified whether
there is a specific length at which the risk of neoplastic progres-
sion increases significantly.
Visible nodularity has been associated with an increased risk
of OAC, although the association seems to indicate the preva-
lence of concurrent HGD or OAC rather than a risk of future
progression. An analysis of oesophagectomy specimens per-
formed for HGD detected by endoscopic biopsies, demon-
strated OAC in 7 of 9 (78%) patients with a visible lesion,
whereas OAC was found in 7 of 22 (32%, p=0.02) patients
without endoscopically visible lesion.170 In other studies, after
endoscopic mucosal resection of lesions with HGD on endo-
scopic biopsy, a final diagnosis of cancer was made in more than
a third of patients.171 172
The presence and size of a hiatal hernia have been associated
with increased OAC risk,160 161 although these are probably
merely surrogate markers for the severity of GORD.
Oesophagitis has been reported to predict a 3.5 times higher
risk of developing HGD/OAC in BO patient compared with
those without.151 The underlying inflammation in oesophagitis
is believed to increase the risk of mutations leading to HGD
and OAC.173
Dysplasia and role of biomarkers
Currently, the grade of dysplasia is the most widely used and
accepted marker for risk stratification in BO, but its value may
be impaired by interobserver disagreement and sampling error.
A correlation between the extent of dysplasia and the risk of
progression to OAC has been sought. In patients with HGD,
this was found to predict risk of progression to OAC (14%
incidence of OAC within 3 years in patients with focal HGD vs
56% in diffuse HGD).174 Additionally, an association has also
been reported between the extent of LGD (measured by the
total number and fraction of dysplastic crypts) and the risk of
progression to OAC.175
There have been a range of attempts to identify further bio-
markers supporting or even replacing dysplasia as a risk strati-
fier. These have been extensively reviewed in two excellent
recent reviews, including markers of genomic instability, tumour
suppressor loci abnormalities, epigenetic changes, proliferation
markers, cell cycle predictors and immunohistochemical
markers.176 177 Of all potential biomarkers, immunohistochem-
istry for nuclear p53 currently holds out the best prospects for
risk stratification in clinical practice, as it can be fairly easily
applied, has demonstrated ability to improve the reproducibility
of a diagnosis of dysplasia, and can also be a predictor of neo-
plastic progression.178 179 In a histopathological study on the
impact of adding p53 immunohistochemistry to histology for
classification of dysplasia, weighted kappa scores between pairs
of pathologists showed substantial agreement, and improved
after p53 immunohistochemistry.180 We previously observed an
increased risk of development of HGD/OAC in the presence of
aberrant p53 expression (HR 6.5, 95% CI 2.5 to 17.1)181 and
recently in a prospective study confirmed that aberrant expres-
sion of p53 protein was a more powerful predictor of neoplastic
progression than histological diagnosis of LGD. The positive
predictive value for neoplastic progression increased from 15%
with histological diagnosis of LGD to 33% with LGD and con-
current aberrant p53 expression.182 As a result of these and
similar studies, the updated BSG guideline for the management
of BO recommends to consider p53 immunohistochemistry as
an adjunct to routine clinical diagnosis.13 Yet, the AGA medical
position statement on the management of BO recommends
against the use of any molecular markers to confirm a diagnosis
of dysplasia or as a method of risk stratification.9
MANAGEMENT OF PATIENTS WITH NDBO REVISITED
Endoscopic surveillance of BO patients without dysplasia
remains the subject of debate, even more so since the publica-
tion of population-based studies that demonstrate a low OAC
risk in BO patients. These new estimates have important impli-
cations for the clinical management of BO patients. First, the
downgraded risk estimates of cancer in NDBO provide little
support for the effectiveness of current surveillance at 3–5-year
intervals. A meta-analysis of cost-effectiveness studies on endo-
scopic surveillance of NDBO, which was based on older and
probably overestimated cancer risk estimates, already concluded
that current surveillance strategies are unlikely to be cost effect-
ive.183 Although the value of dysplasia as a marker for risk
stratification is hampered by interobserver disagreement and
sampling error, all recent population-based cohort studies show
that LGD at index biopsy was associated with a considerably
heightened OAC risk, this, in spite of the fact that most cases
will not have been diagnosed by specialist pathologists. This
raises the question whether long-term surveillance can be
omitted in some BO patients when absence of dysplasia has
been confirmed repeatedly. Given the fact that a large propor-
tion of OAC seems to occur within a year from BO diagnosis, it
remains of paramount importance to perform an adequate
endoscopic inspection at initial diagnosis, combined with
obtaining a sufficient number of biopsy specimens to confidently
assess for dysplasia. A subsequent follow-up endoscopy within
1 year after initial diagnosis, especially in LSBO, should be per-
formed, in order to be more confident of a true absence of
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neoplastic or dysplastic histology. Although current epidemio-
logical risk factors for cancer progression do not discriminate
perfectly between low-risk and high-risk patients, they still
strongly suggest that, in particular, white female SSBO patients
without dysplasia at index diagnosis are the least likely to
benefit from surveillance. In male SSBO patients without dyspla-
sia a stopping rule for surveillance could be implemented after
two endoscopies without dysplasia in non-targeted biopsy sam-
pling. In female LSBO patients, it may be reasonable to extend
further surveillance intervals from the currently proposed 3–
5 years when absence of dysplasia has been confirmed, in par-
ticular, when no additional risk factors, such as smoking and
obesity, are present. In case of a very long segment of BO, given
the poor adherence to surveillance biopsy protocols in daily
clinical practice, referral to a tertiary centre experienced in spe-
cialised imaging modalities may be considered.
A second important implication is that the new cancer risk
estimates advocate against the increasing use of ablation therapy
in NDBO patients. Endoscopic therapy for BO has been one of
the most important developments for clinical practice, and is
now the standard of care for patients with HGD or early
mucosal cancer, preferred to surgery.184 For NDBO, however,
given the low rate of cancer progression, the benefit of such
intervention, even if leading to complete ablation, is unclear. A
cost-usage analysis by Inadomi et al185 suggested that ablation
therapy of NDBO could be the preferred management strategy
if the procedure eliminates the need for long-term endoscopic
surveillance. However, a cost-effectiveness study on the use of
radio-frequency ablation (RFA) for BO by the same study
group,186 based on more recent cancer risk estimates in BO,
found that initial RFA was not cost effective for patients with
NDBO within the range of plausible rates of progression of BO
to OAC, while it might be cost effective for confirmed and
stable LGD. For patients with HGD, initial RFA was more
effective and less costly than endoscopic surveillance.
Additionally, there remain many unanswered questions regard-
ing the durability of the ablation procedure and the need for
endoscopic surveillance after ablation. Sharma et al reported on
three cases of subsquamous neoplasia including two developing
OAC after RFA, highlighting the need for continued meticulous
surveillance with biopsies of neosquamous epithelium, even
after apparent successful eradication of intestinal metaplasia.187
If endoscopic ablation in low-risk BO is applied in practice, it
should therefore only be performed within a trial.
SUMMARY AND FUTURE DIRECTIONS
BO is a common disorder in western countries, and appears to
have a persistent increasing incidence in the general population,
with obesity being the suspected most important driving factor
for the increasing incidence. The increasing incidence heralds a
further increase in OAC incidence in the coming decades, and
emphasises the need for effective preventive strategies. At
present, however, screening cannot be recommended, as the
population at risk is too broadly defined, and current screening
techniques are burdensome and costly. More research is antici-
pated on the development of less invasive and more cost-
effective modalities for detection of BO, as well as on the
development of non-endoscopic markers that can predict pres-
ence of BO.
With recent studies showing much lower cancer risk in BO
than previously anticipated, and the growing emphasis on
healthcare cost containment, the rationale for endoscopic sur-
veillance is likely to come under greater scrutiny. The risk of
OAC among patients with BO is so minor that in the absence of
dysplasia, routine surveillance of such patients is of dubious
value. BO patients with short segments of BO without dysplasia
are the least likely to benefit, and surveillance could be omitted,
especially when other clinical risk factors are absent. In LSBO
patients in whom absence of dysplasia can be confirmed repeat-
edly, it may be reasonable to extend further surveillance inter-
vals from the currently proposed 3–5 years or even longer.
Moreover, the increasing use of endoscopic ablation therapy in
NDBO patients is at present not justifiable outside clinical
studies. Future studies should focus on the development of a
risk score that incorporates demographic, endoscopic, histologic
and molecular risk factors, and on improvement of optical rec-
ognition of dysplasia. Prospective multicenter study with inclu-
sion of a significant number of uncomplicated BO patients and
randomisation to clinical factors and biomarkers are needed.
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